Article
Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.
European journal of clinical pharmacology - 1 Jul 2009
Sugahara Hideyo, Maebara Chiharu, Ohtani Hisakazu, Handa Masanori, Ando Katsumi, Mine Kazunori, Kubo Chiharu, Ieiri Ichiro, Sawada Yasufumi
Abstract excerpt
PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. The aim of this study was to investigate the factors responsible for interindividual variability in the extent of interaction between FVX and alprazolam (ALP). METHODS: Blood samples were taken from 49 depressive patients to determine plasma concentration of FVX, ALP or both. Twenty-four samples were taken...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
